Heidemann, E. and Stoeger, H. and Souchon, R. and Hirschmann, W.-D. and Bodenstein, H. and Oberhoff, C. and Fischer, J. T. and Schulze, M. and Clemens, M. and Andreesen, Reinhard and Mahlke, M. and König, M. and Scharl, A. and Fehnle, K. and Kaufmann, M. (2002) Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 13 (11), pp. 1717-29.
Full text not available from this repository.
BACKGROUND: To determine whether patients with high-risk metastatic breast cancer draw benefit from combination chemotherapy as first-line treatment. PATIENTS AND METHODS: A total of 260 women with measurable metastatic breast cancer fulfilling high-risk criteria, previously untreated with chemotherapy for their metastatic disease, were randomized to receive either mitoxantrone 12 mg/m(2) or the ...
Export bibliographical data
|Institutions:||Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie)|
|Dewey Decimal Classification:||600 Technology > 610 Medical sciences Medicine|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Yes|
|Deposited On:||20 Apr 2010 06:20|
|Last Modified:||20 Apr 2010 06:20|